PPAR-targeted drugs have been demonstrated to confer cardioprotection in cardiovascular diseases (Shiomi et al., 2002; Bulhak et al., 2006), it is therefore possible that these drugs might also serve as a feasible strategy in the treatment of CME. Here, PPARA is linked to cardiovascular disorder.